Passage Bio PASG shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $29 price target.
The firm said the company’s gene therapy platform and UPenn collaboration will create significant value for investors with multiple inflection events approaching in the next 6-12 months.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders.
At the time of publication, shares of Passage Bio were trading 13.2% higher at $14.99. The stock has a 52-week low of $12.10 and a 52-week high of $30.87.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
